Extraskeletal osteosarcoma has a favourable prognosis when treated like conventional osteosarcoma

J Cancer Res Clin Oncol. 2005 Aug;131(8):520-6. doi: 10.1007/s00432-005-0687-7. Epub 2005 May 26.

Abstract

Purpose: The aims of this analysis were to investigate the clinical features of extraskeletal osteosarcoma (ESOS) and examine the outcome after multi-modal therapy.

Methods: The co-operative osteosarcoma study-group database was searched for patients with extraskeletal osteosarcoma. Eligible patients were included in a retrospective analysis of patient, tumour and treatment related variables and outcome. As for conventional osteosarcoma, scheduled treatment included surgery and multi-agent chemotherapy.

Results: Seventeen eligible patients were identified with a median age of 44 years (range, 3-65 years). The thigh was the commonest tumour site. Two patients had a history of previous malignancies and two had primary metastases. Median follow-up was 3.2 years (range: 0.6-7.4 years) and at last follow-up, 11 patients were alive in complete remission, 3 patients were alive with disease and 3 patients had died of their disease. Three-year overall actuarial and event-free survival rates were 77% and 56%, respectively. Patients with macroscopically complete surgical remission had an improved overall survival (P = 0.0004).

Conclusions: The patients in this retrospective study had a surprisingly good survival rate. This may be due to the combination of multi-agent chemotherapy with surgery, and we recommend this approach in the treatment of ESOS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Bone Neoplasms / diagnosis
  • Bone Neoplasms / therapy
  • Chemotherapy, Adjuvant
  • Child
  • Child, Preschool
  • Disease-Free Survival
  • Female
  • Humans
  • Male
  • Middle Aged
  • Osteosarcoma / diagnosis*
  • Osteosarcoma / drug therapy
  • Osteosarcoma / surgery
  • Osteosarcoma / therapy*
  • Prognosis
  • Retrospective Studies
  • Survival Analysis